Binding and Neutralizing Antibody Responses to SARS-CoV-2 in Infants and Young Children Exceed Those in Adults
SARS-CoV-2 infections are frequently milder in children than adults, suggesting that immune responses may vary with age. However, information is limited regarding SARS-CoV-2 immune responses in young children. We compared Receptor Binding Domain binding antibody (RBDAb) and SARS-CoV-2 neutralizing antibody (neutAb) in children aged 0-4 years, 5-17 years, and in adults aged 18-62 years in a SARS-CoV-2 household study. Among 55 participants seropositive at enrollment, children aged 0-4 years had >10-fold higher RBDAb titers than adults (373 vs.35, P <0.0001), and the highest RBDAb titers in 11/12 households with seropositive children and adults. Children aged 0-4 years had 2-fold higher neutAb than adults, resulting in higher binding to neutralizing (B/N)Ab ratios compared to adults (1.9 vs. 0.4 for ID 50 , P=0.0002). Findings suggest that young children mount robust antibody responses to SARS-CoV-2 following community infections. Additionally, these results support using neutAb to measure the immunogenicity of COVID-19 vaccines in children aged 0-4 years.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2021) vom: 21. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karron, Ruth A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 22.04.2022 published: Electronic UpdateIn: JCI Insight. 2022 Mar 22;:. - PMID 35316213 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2021.12.20.21268034 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335165184 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335165184 | ||
| 003 | DE-627 | ||
| 005 | 20231225225235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.12.20.21268034 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335165184 | ||
| 035 | |a (NLM)34981066 | ||
| 035 | |a (PII)2021.12.20.21268034 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karron, Ruth A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Binding and Neutralizing Antibody Responses to SARS-CoV-2 in Infants and Young Children Exceed Those in Adults |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: JCI Insight. 2022 Mar 22;:. - PMID 35316213 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a SARS-CoV-2 infections are frequently milder in children than adults, suggesting that immune responses may vary with age. However, information is limited regarding SARS-CoV-2 immune responses in young children. We compared Receptor Binding Domain binding antibody (RBDAb) and SARS-CoV-2 neutralizing antibody (neutAb) in children aged 0-4 years, 5-17 years, and in adults aged 18-62 years in a SARS-CoV-2 household study. Among 55 participants seropositive at enrollment, children aged 0-4 years had >10-fold higher RBDAb titers than adults (373 vs.35, P <0.0001), and the highest RBDAb titers in 11/12 households with seropositive children and adults. Children aged 0-4 years had 2-fold higher neutAb than adults, resulting in higher binding to neutralizing (B/N)Ab ratios compared to adults (1.9 vs. 0.4 for ID 50 , P=0.0002). Findings suggest that young children mount robust antibody responses to SARS-CoV-2 following community infections. Additionally, these results support using neutAb to measure the immunogenicity of COVID-19 vaccines in children aged 0-4 years | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Quesada, Maria Garcia |e verfasserin |4 aut | |
| 700 | 1 | |a Schappell, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Stephen D |e verfasserin |4 aut | |
| 700 | 1 | |a Knoll, Maria Deloria |e verfasserin |4 aut | |
| 700 | 1 | |a Hetrich, Marissa K |e verfasserin |4 aut | |
| 700 | 1 | |a Veguilla, Vic |e verfasserin |4 aut | |
| 700 | 1 | |a Doria-Rose, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Dawood, Fatimah S |e verfasserin |4 aut | |
| 700 | 0 | |a SEARCh Study Team |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2021) vom: 21. Dez. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:21 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.12.20.21268034 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 21 |c 12 | ||